Jul 12th 2012 - Edison Investment Research today published a report on MediGene entitled "Ally In Asia For EndoTAG". In summary, the report says:
Medigene’s long search for a development partner for its Phase II breast cancer candidate EndoTAG-1 has reached a significant milestone with SynCore Biotechnology acquiring development and commercialisation rights in Asia, Australia and New Zealand. Medigene retains rights in the US and Europe to the paclitaxel-based drug and continues to seek partners for these key territories. Medigene now expects an NDA filing in 2018, so we assume a potential launch in 2019, a two-year delay to our prior estimate, which reduces our valuation by €9m to €87m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »